Immunogenic chemotherapy has been shown to enhance the efficacy of ICIs by promoting tumor infiltration of CD4+ and CD8+ T cells while attenuating the activity of immunosuppressive populations such as Tregs. The gene discussed is CD4; the disease is neoplasm.